Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years Recognition complements the company's recent announcement that it will provide its new gene therapy for a form of genetic hearing loss for free in the United States, reinforcing its commitment to patient access New science-led 2030 responsibility goals reflect Regeneron's commitment to corporate responsibility, from how it innovates to how it operates, for the good of its business and humanity TARRYTOWN, N.Y., May 08, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced it has been named to the Dow Jones Best-in-Class World Index, one of the world's most recognized benchmarks for corporate sustainability performance.